Legal & General Group
QNCX icon

Legal & General Group’s Quince Therapeutics QNCX Stock Holding History

Legal & General Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38
Closed -$47K – 3629
2022
Q1 		$47K Buy
38
+1
+3% +$1.36K ﹤0.01% 3015
2021
Q4 		$95K Buy
37
+1
+3% +$6.1K ﹤0.01% 2921
2021
Q3 		$665K Buy
36
+21
+140% +$334K ﹤0.01% 2340
2021
Q2 		$157K Buy
15
+3
+25% +$25.2K ﹤0.01% 2599
2021
Q1 		$86K Hold
12
– – ﹤0.01% 2660
2020
Q4 		$68K Hold
12
– – ﹤0.01% 2709
2020
Q3 		$124K Sell
12
-4
-25% -$36.4K ﹤0.01% 2435
2020
Q2 		$147K Buy
16
+7
+78% +$64.1K ﹤0.01% 2431
2020
Q1 		$84K Sell
9
-3
-25% -$29.6K ﹤0.01% 2462
2019
Q4 		$131K Buy
12
+10
+500% +$60.3K ﹤0.01% 2512
2019
Q3 		$12K Hold
2
– – ﹤0.01% 3241
2019
Q2 		$20K Buy
+2
New +$11.9K ﹤0.01% 3196

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Legal & General Group's QNCX Position: Q2 2022 in Review

Legal & General Group sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 38 shares — an estimated $47K sold.

Legal & General Group first reported a position in QNCX in Q2 2019 and held it in 12 quarters. The position peaked at $665K in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Legal & General Group reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 38 Quince Therapeutics shares in Q2 2022, an estimated $47K.
  • Legal & General Group first reported a position in Quince Therapeutics in Q2 2019 and held it in 12 quarters.
  • Legal & General Group's Quince Therapeutics position peaked at $665K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.